by Dr. Ed Weber | Jul 20, 2022 | PCa Commentary
Provenge (Dendreon, Inc, ‘Sipuleucel-T’) is an autologous (i.e., based on a patient’s own cells) vaccine targeted to the highly expressed prostatic acid phosphatase (PAP) antigen on malignant prostate cells. It was FDA approved based on the IMPACT trial reporting a...
by Dr. Ed Weber | Jun 1, 2022 | PCa Commentary
Years before there was even a glimmer of technical possibility for effective immunotherapy, there was great hope for harassing the immune system to combat cancer. The earliest realization of this hope came with the FDA approval of Provenge in April 2010 and...
by Dr. Ed Weber | May 17, 2022 | PCa Commentary
[Prostate Cancer Commentary Vol. 143 PCa Commentary #143: ANTI-PSMA 177-LUTETIUM RADIOLIGAND THERAPY discusses the mechanism of action of 177Lu therapy, its background and outcome of early studies] (control+click above link to follow or visit...
by Dr. Ed Weber | Apr 19, 2022 | PCa Commentary
When the PSA is elevated following initial potentially curative treatment with prostatectomy or radiation therapy, the customary management response has been hormone suppression with Lupron, Degarilix or Relugolix. This Commentary highlights an alternative...
by Dr. Ed Weber | Mar 10, 2022 | PCa Commentary, Uncategorized
Heterogeneity is the Achilles heel of prostate cancer staging. Intermediate-risk cancers with Gleason Score 3+4 and 4+3 (i.e., Grade Groups 2 and 3) are especially fraught with this complexity. A report, “Molecular Analysis of Low-Grade Prostate Cancer Using...
